Many investigators in different parts of the world have determined their own starting dose for capecitabine, usually based on their experience of toxic events within the population of patients ...

[12] It might be possible to develop a panel of SNPs that could be used to prospectively select patients who would benefit most from capecitabine therapy and those who might require dose ...